A prominent research firm, Cognizance Market Research added a cutting-edge industry report on the “Global Acute Viral Rhinosinusitis Treatment Market”. The report studies the current as well as past growth trends and opportunities for the market to gain valuable insights during the forecast period from 2023 to 2030.
Global Acute Viral Rhinosinusitis Treatment Market Analysis:
According to cognizance market research, the global acute viral rhinosinusitis treatment market was valued at US$ 1,967.3 Million in 2022 and is anticipated to reach US$ 3,879.0 Million by the end of 2030 with a CAGR of 8.9% from 2023 to 2030.
What is Global Acute Viral Rhinosinusitis Treatment Market?
Rhinosinusitis is a common medical condition that many patients seek treatment for. There are different types of rhinosinusitis such as acute, subacute, recurrent acute and chronic rhinosinusitis. Acute rhinosinusitis can be caused by bacteria or virus. However, most cases of acute rhinosinusitis are caused by viral infections that accompany the common cold. For patients with mild symptoms such as mild pain and temperature less than 101°F (38.3°C), symptomatic treatment with analgesics, decongestants, and saline nasal irrigation is appropriate.
Acute rhinosinusitis (ARS) typically lasts less than four weeks and is usually caused by a viral infection associated with the common cold. The different types of rhinosinusitis are classified based on the duration of symptoms. These include acute rhinosinusitis, sub-acute rhinosinusitis, chronic rhinosinusitis, and recurrent acute rhinosinusitis.
The market offers a variety of treatment options, including over-the-counter drugs such as nasal decongestants, antihistamines, and pain relievers, as well as prescription drugs such as antibiotics and steroids. There are also various therapeutic approaches available, such as home remedies, steam inhalation, and other natural remedies. The market for acute viral rhinosinusitis treatment is expected to grow significantly in the coming years due to the increasing prevalence of acute viral rhinosinusitis and growing awareness about various treatment options.
Global Acute Viral Rhinosinusitis Treatment Market Outlook:
Antibiotics have been shown to often be ineffective in treating the symptoms of bacterial acute rhinosinusitis (ABRS). Therefore, it is now widely understood that it is important to evaluate each patient’s condition before prescribing antibiotics, considering the negative consequences, such as drug resistance that can result from their overuse.
In contrast, intranasal corticosteroids (ARS) have been shown to be helpful in treating post-viral acute rhinosinusitis. To meet the demand for these treatments, manufacturers are increasing their production of saline nasal irrigation and over-the-counter analgesics.
Amoxicillin and clavulanate are recommended for people at risk of developing pneumococcal resistance. This combination therapy is becoming more widely available from companies in the Global Acute Viral Rhinosinusitis Treatment Market as the initial treatment of choice for ABRS patients without risk factors for resistance.
Children are more commonly prescribed amoxicillin and clavulanate than adults. However, there is now an increasing emergence of antimicrobial resistance among respiratory pathogens, leading to the need for more research and development efforts in routine conjugated pneumococcal vaccination for children.
A higher dose of amoxicillin and clavulanate is recommended for patients at high risk of pneumococcal resistance. Due to the increasing microbial resistance to antibiotics, amoxicillin or amoxicillin-clavulanate are becoming more popular choices for treating ABRS.
Nasal saline irrigation has been found to effectively remove or reduce debris and pathogens from the nares, resulting in symptomatic relief. Companies in the Global Acute Viral Rhinosinusitis Treatment Market are increasing their production of topical intranasal therapies to reduce congestion in patients. Topical corticosteroid nasal sprays can help reduce mucosal inflammation, reducing stenosis of the sinus drainage pathways. Therefore, nasal corticosteroids are expected to be the second-highest revenue earner among all treatment types in the Global Acute Viral Rhinosinusitis Treatment Market.
Here’s the corrected paragraph with some adjustments for clarity and consistency:
Based on treatment options, the global market for acute viral rhinosinusitis treatment is categorized into nasal sprays, nasal corticosteroids, decongestants, NSAIDs, and other therapies.
In terms of the route of administration, the global market for acute viral rhinosinusitis treatment is classified into topical, nasal, oral, and injectable methods.
As for distribution channels, the global market for the treatment of acute viral rhinosinusitis is divided into online pharmacies, retail pharmacies, and hospital pharmacies.
Based on the type of infection, the global market for acute viral rhinosinusitis treatment is further segmented into rhinovirus (picornavirus) and non-rhinovirus infections.
North America currently holds a dominant position in the global market for acute viral rhinosinusitis treatments, and this trend is expected to continue throughout the forecast period. Acute viral rhinosinusitis is characterized by the rapid worsening or onset of symptoms in patients with chronic sinusitis, often accompanied by purulent drainage from the sinuses, as observed during nasal endoscopy.
In the Asia Pacific region, increased healthcare spending and greater awareness of sinusitis are anticipated to drive market expansion. Additionally, a rise in investment in pharmaceutical drug research and development is projected to further fuel market growth in this region.
Europe is also expected to experience market growth due to the increased demand for medications to treat acute viral rhinosinusitis. Factors such as a focus on discovering novel treatment medications and heightened awareness of acute viral rhinosinusitis are likely to be driving forces in this region’s market expansion.
The report offers the revenue of the global acute viral rhinosinusitis treatment market for the period 2020-2030, considering 2020 and 2021 as historical years, 2022 as the base year, and 2023 to 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global acute viral rhinosinusitis treatment market for the forecast period. The global acute viral rhinosinusitis treatment market report provides insights and in-depth analysis into developments impacting enterprises and businesses on a regional and global level. The report covers the global acute viral rhinosinusitis treatment market performance in terms of revenue contribution from several segments and comprises a detailed analysis of key drivers, trends, restraints, and opportunities prompting revenue growth of the global acute viral rhinosinusitis treatment market.
The report has been prepared after wide-ranging secondary and primary research. Secondary research included internet sources, numerical data from government organizations, trade associations, and websites. Analysts have also employed an amalgamation of bottom-up and top-down approaches to study numerous phenomena in the Global Acute Viral Rhinosinusitis Treatment Market. Secondary research involved a detailed analysis of significant players’ product portfolios. Literature reviews, press releases, annual reports, white papers, and relevant documents have been also studied to understand the global acute viral rhinosinusitis treatment market. Primary research involved a great extent of research efforts, wherein experts carried out interviews telephonic as well as questioner-based with industry experts and opinion-makers.
The report includes an executive summary, along with a growth pattern of different segments included in the scope of the study. The Y-o-Y analysis with elaborate market insights has been provided in the report to comprehend the Y-o-Y trends in the Global acute viral rhinosinusitis treatment market. Additionally, the report focuses on altering competitive dynamics in the global market. These indices serve as valued tools for present market players as well as for companies interested in participating in the Global Acute Viral Rhinosinusitis Treatment Market. The subsequent section of the Global Acute Viral Rhinosinusitis Treatment Market report highlights the USPs, which include key industry events (product launch, research partnership, acquisition, etc.), technology advancements, pipeline analysis, prevalence data, and regulatory scenario.
Global Acute Viral Rhinosinusitis Treatment Market Competitive Landscape:
There are several small and major firms participating in the highly fragmented global acute viral rhinosinusitis treatment market. The new strategies formed by companies revolve around accuracy and precision. The new technology used by brands is helping them launch new types of products like seizure sleep monitors and smartwatch seizure detection devices. The following are some of the major market participants:
The report explores the competitive scenario of the Global Acute Viral Rhinosinusitis Treatment Market. Major players working in the Global Acute Viral Rhinosinusitis Treatment Market have been named and profiled for unique commercial attributes. Company overview (company description, product portfolio, geographic presence, employee strength, Key management, etc.), financials, SWOT analysis, recent developments, and key strategies are some of the features of companies profiled in the Global Acute Viral Rhinosinusitis Treatment Market report.
Global Acute Viral Rhinosinusitis Treatment Market, By Treatment:
Global Acute Viral Rhinosinusitis Treatment Market, By Route of Administration:
Global Acute Viral Rhinosinusitis Treatment Market, By Distribution Channel:
Global Acute Viral Rhinosinusitis Treatment Market, By Infection Type:
Global Acute Viral Rhinosinusitis Treatment Market, By region:
It was Valued at US$ 1,967.3 million in 2022.
It is projected to reach more than US$ 3,879.0 Million by 2030.
It is anticipated to be 8.9%from 2023 to 2030.
Trend: Increased Viral Infections, Advances in Diagnosis, Rising Antibiotic Stewardship, etc.
Driver: Growing Incidence, Awareness and Education, Research and Development etc.
Opportunities: Development of Antiviral Drugs, Consumer Preference for Natural Remedies, etc.
Challenges: Antibiotic Overuse, Regulatory Hurdles, etc
Amneal Pharmaceuticals LLC, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Dr. Reddy’s Laboratories Inc., Eli Lilly and Company, Fresenius Kabi USA LLC, GlaxoSmithKline plc, Hikma Pharmaceuticals plc, Janssen Pharmaceuticals Inc., Merck & Co. Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Inc
Acute Viral Rhinosinusitis Treatment Market
Don’t Miss Out On The Biggest Savings Of The Year!
Get insights that lead to new growth opportunities
We can customize every report – free of charge – including purchasing stand-alone sections or country-level reports
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail